Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback